-
Views
-
Cite
Cite
Chadwick D. Miller, Anindita Banerjee, Kenneth W. Mahaffey, Michael C. Kontos, Gregory Fermann, Charles V. Pollack, Elliott Antman, Philip Aylward, Shaun G. Goodman, Renato Santos, James J. Ferguson, Robert M. Califf, James W. Hoekstra, Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial, European Heart Journal, Volume 28, Issue 9, May 2007, Pages 1079–1084, https://doi.org/10.1093/eurheartj/ehm016
Close - Share Icon Share
Patients with myocardial infarction (MI) presenting immediately after symptom onset may be treated less aggressively due to their non-elevated troponin status. We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI.
This study analysed data from the Superior Yield of the New strategy of Enoxaparin, Revascularisation, and Glycoprotein IIb/IIIa inhibitors (SYNERGY) trial, which enrolled patients meeting at least two of the following: age ≥ 60 years, elevated cardiac biomarkers, or ST-segment changes. Patients were stratified by troponin results obtained within 12 h of presentation: EMI [initial troponin (−), second troponin (+)], MI [initial troponin (+)], and no MI at enrolment [first and second troponin (−)]. Comparisons were made using Wilcoxon rank-sum and χ2 tests. Of the 8309 patients with complete data, 5503 (66%) had MI, 1686 (20%) had EMI, and 1120 (13%) had no MI. Treatment patterns prior to enrolment were similar among EMI and MI patients [aspirin (88 vs. 86%), beta-blockers (62 vs. 61%), heparin (83 vs. 81%), and glycoprotein IIb/IIIa inhibitors (23 vs. 24%)]. Similar rates of percutaneous coronary intervention (48 vs. 50%) and coronary artery bypass grafting (21 vs. 22%) were seen after enrolment. Patients presenting with MI had a higher rate of death or recurrent MI compared with patients with EMI [16 vs. 13%, adjusted OR 1.22 (95% CI 1.04, 1.44)].
Initial treatment patterns were similar among patients with EMI and MI in the SYNERGY trial. Patients with EMI had lower rates of death or re-infarction at 30 days compared with patients presenting with positive troponin results.
